IMMUNEXT
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.
IMMUNEXT
Industry:
Biotechnology
Address:
Lebanon, New Hampshire, United States
Country:
United States
Website Url:
http://www.immunext.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Font Awesome Apache Wordpress Plugins Mobile Non Scaleable Content Google Apps For Business
Current Employees Featured
Official Site Inspections
http://www.immunext.com Semrush global rank: 4.83 M Semrush visits lastest month: 1.87 K
- Host name: 65-254-250-103.yourhostingaccount.com
- IP address: 65.254.250.103
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803
More informations about "ImmuNext"
ImmuNext - Crunchbase Company Profile & Funding
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program …See details»
Team – ImmuNext
Dr. Noelle is co-founder and Vice Chair of ImmuNext, and Professor of Immunology at the Geisel School of Medicine at Dartmouth. His laboratory discovered the natural CD40 ligand, CD154, and the checkpoint regulator, …See details»
ImmuNext - LinkedIn
ImmuNext is developing immune-based therapeutics to treat patients with immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious disease.See details»
ImmuNext Company Profile 2024: Valuation, Funding …
ImmuNext General Information Description. Operator of a biotechnology company intended to modulate the immune system to treat cancer and autoimmune diseases. The company primarily is engaged in conducting biotechnology …See details»
Small Company Makes Big Strides in Treating Autoimmune …
Jun 28, 2024 ImmuNext researchers focused on developing a second drug by re-engineering the first. “We were able to modify the original [cancer] drug to do the opposite, which is to slow …See details»
Small Company Makes Big Strides in Treating Autoimmune …
Jan 31, 2020 In 2013 ImmuNext received both a Phase I STTR and a Phase II SBIR to investigate another target of immune malfunction which could potentially treat disorders like …See details»
Sanofi and ImmuNext Enter into Agreement to Develop …
Jan 9, 2017 BRIDGEWATER, N.J. and LEBANON, N.H., Jan. 9, 2017 /PRNewswire/ -- Sanofi and ImmuNext, Inc., announced today an agreement focused on the development of a novel …See details»
Lilly, ImmuNext Launch Up-to-$605M+ Autoimmune Disease …
Mar 27, 2019 Eli Lilly will partner with ImmuNext to study and develop a preclinical novel potential target for autoimmune disease treatments, the companies said, through an up-to …See details»
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
NEW YORK, NY, May 9, 2024 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for …See details»
Partnered Assets - ImmuNext
ImmuNext is developing immune-based therapeutics to treat patients with immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious disease. …See details»
ImmuNext Enters into a Strategic Alliance to Develop Novel …
Dec 20, 2016 The ImmuNext technology is based on discoveries made in Dr. Randolph Noelle’s labs at the Geisel School of Medicine at Dartmouth College. Dr. Noelle is co-founder and CSO …See details»
Lilly and ImmuNext enter autoimmune disease research alliance
Mar 28, 2019 ImmuNext may also receive tiered royalties on product sales. The companies intend to enter a three-year research partnership for the target’s development. ImmuNext chief …See details»
Sanofi licences ImmuNext autoimmune disease drug
Jan 16, 2017 ImmuNext could bank $500 million in milestone payments, as well as tiered royalties up to double digits on sales of products. “The immunoregulatory molecule, CD40L, is …See details»
Sanofi and ImmuNext Enter into Agreement to Develop …
Jan 9, 2017 BRIDGEWATER, N.J. and LEBANON, N.H., Jan. 9, 2017 /PRNewswire/ -- Sanofi and ImmuNext, Inc., announced today an agreement focused on the development of a novel …See details»
Lilly teams with ImmuNext for autoimmune drug - Chemical
Mar 29, 2019 Eli Lilly and Company will pay ImmuNext $40 million as part of a research pact focused on an autoimmune disease drug target. The companies have not identified the target …See details»
Small Company Makes Big Strides in Treating Autoimmune …
Jan 31, 2020 ImmuNext founders Randolph Noelle and David DeLucia zeroed in on one area that could benefit from early de-risking: drugs that control a malfunctioning immune system. …See details»
Sanofi, Immunext partner to develop autoimmune therapies
Jan 10, 2017 Immunext could get up to $500 million in potential milestone payments, plus up to double-digit tiered royalties on product sales, through the deal. Dive Insight: Preclinical data …See details»
Autoimmune Collab between ImmuNext and Sanofi Could Yield …
Jan 9, 2017 ImmuNext has entered into an agreement with Sanofi to develop a novel protein for the treatment of autoimmune disorders. Under the agreement, milestone payments to …See details»
Latest News - ImmuNext
BRIDGEWATER, N.J. and LEBANON, N.H., Jan. 9, 2017 /PRNewswire/ –Sanofi and ImmuNext, Inc., announced today an agreement focused on the development of a novel antibody with the …See details»